Clinical Trial Detail

NCT ID NCT03425643
Title Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Pemetrexed Disodium

Cisplatin + Gemcitabine + Pembrolizumab

Pembrolizumab

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Cisplatin + Gemcitabine

Age Groups: adult senior

No variant requirements are available.